Less-discussed side effects of antidepressants: sweating, vivid dreams, teeth clenching, sexual function

Sexual side effects of antidepressants are rarely reported unless people are asked directly. This is a caveat from the meta-analysis itself.

🩺 Four less-discussed topics: excessive sweating, vivid dreams, teeth clenching, sexual function. Reports of sweating were 2.93 times higher with SSRIs and 3.17 times higher with SNRIs than with placebo; an analysis of 76 studies and 28,544 participants found no significant increase for fluvoxamine, bupropion, or vortioxetine. Vivid dreams are a separate observation: both taking and stopping SSRIs and SNRIs appear to intensify dreams. Sexual dysfunction, meanwhile, is not uncommon: when people are asked directly, reported rates range from 25.8% to 80.3%. There are case reports of teeth clenching, but its incidence is unknown; symptoms can also emerge three to four weeks after starting the medication.

Addiction is a separate topic. Discontinuation symptoms are real: after subtracting the rate in the placebo group, they affect approximately 15%, or one in every six to seven people. However, the tolerance and compulsive use that characterize addiction are exceptionally rare with antidepressants. Still, the picture is not one-sided: in a voluntary survey of 867 patients, 40% reported feeling addicted. There is also long-term evidence: across thirty-one randomized trials, continuing treatment reduced the risk of relapse by two-thirds; relapse rates were 41% with placebo and 18% with active treatment.

✅ During your appointment: bring up all four yourself; note how many weeks after a medication or dose change the symptom appeared; describe its severity in one sentence; ask about options for adjusting treatment (dose, switching medications, adding another medication; a Cochrane review examined sildenafil in men and high-dose bupropion in women); do not stop the medication on your own—tapering may take longer than four weeks.

Sources: Beyer ve ark. (2017), Depress Anxiety · Tribl ve ark. (2013), Sleep Med Rev · Serretti ve Chiesa (2009), J Clin Psychopharmacol · Garrett ve Hawley (2018), Neurol Clin Pract · Haddad (1999), J Psychopharmacol · Henssler ve ark. (2024), Lancet Psychiatry · Henssler ve ark. (2019), Dtsch Arztebl Int · Geddes ve ark. (2003), Lancet · Taylor ve ark. (2013), Cochrane Database Syst Rev · Read (2020), Addict Behav

This content is not diagnostic or treatment advice.

Download the presentation file

For scientific sources → CLICK HERE